{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:07:53Z","timestamp":1747159673192,"version":"3.40.5"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ejpn-journal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejpn.2024.10.013","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T01:05:36Z","timestamp":1730423136000},"page":"174-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immune-mediated neurological syndromes associated with childhood cancers"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5472-1813","authenticated-orcid":false,"given":"Thomas","family":"Rossor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Gadian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios","family":"Kaliakatsos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5930-3530","authenticated-orcid":false,"given":"Paola","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7738-8910","authenticated-orcid":false,"given":"Ming","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"1894","series-title":"Lehrbuch Der Nervenkrankheiten F\u00fcr \u00c4rzte Und Studierende","author":"Oppenheim","key":"10.1016\/j.ejpn.2024.10.013_bib1"},{"issue":"7","key":"10.1016\/j.ejpn.2024.10.013_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41582-018-0024-9","article-title":"Neuroimmune disorders of the central nervous system in children in the molecular era","volume":"14","author":"Wells","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.ejpn.2024.10.013_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/1352458519887328","article-title":"Race and ethnicity on MS presentation and disease course: ACTRIMS forum 2019","volume":"26","author":"Amezcua","year":"2020","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.ejpn.2024.10.013_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/NXI.0000000000000837","article-title":"Treatment and outcome of aquaporin-4 antibody\u2013positive NMOSD: a multinational pediatric study","volume":"7","author":"Paolilo","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"4","key":"10.1016\/j.ejpn.2024.10.013_bib5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/dmcn.12882","article-title":"Symptomatic treatment of children with anti-NMDAR encephalitis","volume":"58","author":"Mohammad","year":"2016","journal-title":"Dev. Med. Child Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.10.013_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04332-3","article-title":"A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica","volume":"9","author":"Estrada","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.ejpn.2024.10.013_bib7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/NXI.0000000000001085","article-title":"Genome-wide association study identifies 2 new loci associated with anti-NMDAR encephalitis","volume":"8","author":"Tietz","year":"2021","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"issue":"10","key":"10.1016\/j.ejpn.2024.10.013_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.14274","article-title":"Development and validation of a targeted next-generation sequencing gene panel for children with neuroinflammation","volume":"2","author":"McCreary","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.ejpn.2024.10.013_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/dmcn.15694","article-title":"Immune-mediated encephalitis","volume":"66","author":"Rossor","year":"2024","journal-title":"Dev. Med. Child Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.10.013_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.ejpn.2024.10.013_bib11","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol neuroinflammation"},{"issue":"3","key":"10.1016\/j.ejpn.2024.10.013_bib12","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001153","article-title":"Diagnosis and management of opsoclonus-myoclonus-ataxia syndrome in children","volume":"9","author":"Rossor","year":"2022","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.ejpn.2024.10.013_bib13","first-page":"275","article-title":"Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004","volume":"vol. 228","author":"Matthay","year":"2005"},{"issue":"2","key":"10.1016\/j.ejpn.2024.10.013_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejpn.2009.03.002","article-title":"A prospective study of the presentation and management of dancing eye syndrome\/opsoclonus-myoclonus syndrome in the United Kingdom","volume":"14","author":"Ki Pang","year":"2010","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"SEP","key":"10.1016\/j.ejpn.2024.10.013_bib15","first-page":"153","article-title":"Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study","volume":"8","author":"Pranzatelli","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejpn.2024.10.013_bib16","first-page":"663","volume":"vol. 7","author":"Cellucci","year":"2020"},{"key":"10.1016\/j.ejpn.2024.10.013_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jneuroim.2008.05.033","article-title":"Autoantibodies in childhood opsoclonus-myoclonus syndrome","volume":"201\u2013202","author":"Blaes","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ejpn.2024.10.013_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-oncology: emerging targets and combination therapies","volume":"8","author":"Marshall","year":"2018","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.ejpn.2024.10.013_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112879","article-title":"Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma","volume":"42","author":"Rosenberg","year":"2023","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.ejpn.2024.10.013_bib20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2002.20.5.1209","article-title":"Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan","volume":"20","author":"Yamamoto","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ejpn.2024.10.013_bib21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00428-002-0747-1","article-title":"Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases","volume":"442","author":"Gambini","year":"2003","journal-title":"Virchows Arch."},{"issue":"1","key":"10.1016\/j.ejpn.2024.10.013_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2352-4642(17)30130-X","article-title":"Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial","volume":"2","author":"de Alarcon","year":"2018","journal-title":"Lancet Child Adolesc Heal"},{"key":"10.1016\/j.ejpn.2024.10.013_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jneuroim.2015.07.007","article-title":"Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome","volume":"286","author":"Panzer","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.ejpn.2024.10.013_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/mds.22941","article-title":"B cell depletion therapy for new-onset opsoclonus-myoclonus","volume":"25","author":"Pranzatelli","year":"2010","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.ejpn.2024.10.013_bib25","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-3114","article-title":"Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life","volume":"128","author":"Brunklaus","year":"2011","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.ejpn.2024.10.013_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/children7090103","article-title":"Evolving cognitive dysfunction in children with neurologically stable opsoclonus\u2013myoclonus syndrome","volume":"7","author":"Goh","year":"2020","journal-title":"Children"},{"key":"10.1016\/j.ejpn.2024.10.013_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pediatrneurol.2023.05.006","article-title":"An international pediatric-onset opsoclonus-myoclonus ataxia syndrome registry and clinical research network: development, progress, and vision","volume":"148","author":"Kerr","year":"2023","journal-title":"Pediatr. Neurol."},{"issue":"12","key":"10.1016\/j.ejpn.2024.10.013_bib28","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.ejpn.2024.10.013_bib29","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/dmcn.13579","article-title":"High sensitivity and specificity in proposed clinical diagnostic criteria for anti-N-methyl-D-aspartate receptor encephalitis","volume":"59","author":"Ho","year":"2017","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ejpn.2024.10.013_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.seizure.2015.04.005","article-title":"CSF findings in patients with anti-N-methyl-d-aspartate receptor-encephalitis","volume":"29","author":"Wang","year":"2015","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.ejpn.2024.10.013_bib31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.ejpn.2024.10.013_bib32","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/brain\/awac088","article-title":"Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis","volume":"145","author":"Al-Diwani","year":"2022","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.ejpn.2024.10.013_bib33","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamaneurol.2021.3188","article-title":"Use and safety of immunotherapeutic management of N-Methyl-d-Aspartate receptor antibody encephalitis: a meta-analysis","volume":"78","author":"Nosadini","year":"2021","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.ejpn.2024.10.013_bib34","article-title":"International consensus recommendations for the treatment of pediatric NMDAR antibody encephalitis","volume":"8","author":"Nosadini","year":"2021"},{"issue":"1","key":"10.1016\/j.ejpn.2024.10.013_bib35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acn3.51494","article-title":"Clinical features, investigations, and outcomes of pediatric limbic encephalitis: a multicenter study","volume":"9","author":"Sabanathan","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"10.1016\/j.ejpn.2024.10.013_bib36","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ejpn.2017.09.001","article-title":"Immune-mediated neurological syndromes: old meets new","volume":"21","author":"Rossor","year":"2017","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.10.013_bib37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/MOP.0b013e3283350d3e","article-title":"Immunotherapy of childhood cancer: from biologic understanding to clinical application","volume":"22","author":"Wayne","year":"2010","journal-title":"Curr. Opin. Pediatr."},{"issue":"17","key":"10.1016\/j.ejpn.2024.10.013_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174364","article-title":"Paving the way for immunotherapy in pediatric acute myeloid leukemia: current knowledge and the way forward","volume":"13","author":"Koedijk","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.ejpn.2024.10.013_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9121798","article-title":"Enhancing the potential of immunotherapy in paediatric sarcomas: breaking the immunosuppressive barrier with receptor tyrosine kinase inhibitors","volume":"9","author":"Fleuren","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejpn.2024.10.013_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1059885","article-title":"Editorial: complexity of tumor microenvironment: a major culprit in cancer development, volume II","volume":"13","author":"Bukhari","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.10.013_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40272-021-00482-y","article-title":"Immunotherapies for pediatric solid tumors: a targeted update","volume":"24","author":"Gupta","year":"2022","journal-title":"Paediatr Drugs"},{"issue":"4","key":"10.1016\/j.ejpn.2024.10.013_bib42","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10555-019-09819-z","article-title":"Immunotherapies for pediatric cancer: current landscape and future perspectives","volume":"38","author":"Hutzen","year":"2019","journal-title":"Cancer Metastasis Rev."},{"issue":"12","key":"10.1016\/j.ejpn.2024.10.013_bib43","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrclinonc.2014.177","article-title":"Immune-based therapies for childhood cancer","volume":"11","author":"Mackall","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejpn.2024.10.013_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102973","article-title":"PARP and PD-1\/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer","volume":"152","author":"Post","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"10","key":"10.1016\/j.ejpn.2024.10.013_bib45","article-title":"Expression of carcinoma, apoptosis, and cell-death\u2013related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells","volume":"66","author":"Ray","year":"2019","journal-title":"Pediatr Blood \\& Cancer"},{"issue":"4","key":"10.1016\/j.ejpn.2024.10.013_bib46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/pbc.25359","article-title":"Going back to class I: MHC and immunotherapies for childhood cancer","volume":"62","author":"Haworth","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.ejpn.2024.10.013_bib47","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","article-title":"Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors","volume":"98","author":"Stein","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejpn.2024.10.013_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102189","article-title":"Neurological complications of cancer immunotherapy","volume":"97","author":"Roth","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.ejpn.2024.10.013_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11899-023-00714-7","article-title":"Blinatumomab in practice","volume":"19","author":"Lantz","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.ejpn.2024.10.013_bib50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/16078454.2018.1549802","article-title":"Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin\u2019s lymphoma: a systemic review and meta-analysis","volume":"24","author":"Yu","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.ejpn.2024.10.013_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.929122","article-title":"The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"10","author":"Marrapodi","year":"2022","journal-title":"Front Pediatr"},{"issue":"14","key":"10.1016\/j.ejpn.2024.10.013_bib52","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejpn.2024.10.013_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081919","article-title":"Clinical phenotype and management of severe neurotoxicity observed in patients with neuroblastoma treated with dinutuximab beta in clinical trials","volume":"14","author":"Wieczorek","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.ejpn.2024.10.013_bib54","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejpn.2024.10.013_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.ejpn.2024.10.013_bib56","doi-asserted-by":"crossref","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","article-title":"Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes","volume":"95","author":"Sechi","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejpn.2024.10.013_bib57","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother cancer"},{"issue":"9","key":"10.1016\/j.ejpn.2024.10.013_bib58","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.mayocp.2019.02.003","article-title":"Neurologic autoimmunity in the era of checkpoint inhibitor cancer immunotherapy","volume":"94","author":"Zekeridou","year":"2019","journal-title":"Mayo Clin Proc."},{"issue":"6","key":"10.1016\/j.ejpn.2024.10.013_bib59","article-title":"Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors","volume":"6","author":"Vogrig","year":"2019","journal-title":"Neurol Neuroimmunol \\& Neuroinflammation"},{"issue":"16","key":"10.1016\/j.ejpn.2024.10.013_bib60","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.ejpn.2024.10.013_bib61","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejpn.2024.10.013_bib62","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","article-title":"Central nervous system complications associated with immune checkpoint inhibitors","volume":"91","author":"Vogrig","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.ejpn.2024.10.013_bib63","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1093\/brain\/aww225","article-title":"CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model","volume":"139","author":"Yshii","year":"2016","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.ejpn.2024.10.013_bib64","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41582-023-00776-4","article-title":"Origins and immunopathogenesis of autoimmune central nervous system disorders","volume":"19","author":"Ramanathan","year":"2023","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"10.1016\/j.ejpn.2024.10.013_bib65","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/acn3.51213","article-title":"HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor","volume":"7","author":"Chang","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"10.1016\/j.ejpn.2024.10.013_bib66","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ana.24715","article-title":"CTLA4 as immunological checkpoint in the development of multiple sclerosis","volume":"80","author":"Gerdes","year":"2016","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.ejpn.2024.10.013_bib67","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2349796","article-title":"Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis","volume":"56","author":"Willyanto","year":"2024","journal-title":"Ann Med"},{"issue":"25","key":"10.1016\/j.ejpn.2024.10.013_bib68","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejpn.2024.10.013_bib69","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","article-title":"Neurological updates: neurological complications of CAR-T therapy","volume":"268","author":"Tallantyre","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.ejpn.2024.10.013_bib70","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ejpn.2024.10.013_bib71","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE) and the European haemato","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"3","key":"10.1016\/j.ejpn.2024.10.013_bib72","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.ejpn.2024.10.013_bib73","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejpn.2024.10.013_bib74","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ejpn.2024.10.013_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"9967","key":"10.1016\/j.ejpn.2024.10.013_bib76","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.ejpn.2024.10.013_bib77","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/ijc.34815","article-title":"GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma","volume":"154","author":"Mora","year":"2024","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.ejpn.2024.10.013_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071276","article-title":"Immunotherapeutic strategies for the treatment of glioblastoma: current challenges and future perspectives","volume":"16","author":"Salvato","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ejpn.2024.10.013_bib79","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamaoncol.2022.5999","article-title":"Effect of oral \u03b2-glucan on antibody response to ganglioside vaccine in patients with high-risk neuroblastoma: a phase 2 randomized clinical trial","volume":"9","author":"Cheung","year":"2023","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ejpn.2024.10.013_bib80","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/1078-0432.CCR-13-1012","article-title":"Phase I trial of a bivalent gangliosides vaccine in combination with \u03b2-glucan for high-risk neuroblastoma in second or later remission","volume":"20","author":"Kushner","year":"2014","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"issue":"23","key":"10.1016\/j.ejpn.2024.10.013_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235802","article-title":"Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: results from compassionate-use treatments","volume":"14","author":"Klingel","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ejpn.2024.10.013_bib82","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ejpn.2024.10.013_bib83","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/archdischild-2016-311284","article-title":"Developing immunotherapies for childhood cancer","volume":"102","author":"Capsomidis","year":"2016","journal-title":"Arch Dis Child Educ \\& Pract Ed"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824001661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824001661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T01:10:24Z","timestamp":1732929024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379824001661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":83,"alternative-id":["S1090379824001661"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.10.013","relation":{},"ISSN":["1090-3798"],"issn-type":[{"type":"print","value":"1090-3798"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-mediated neurological syndromes associated with childhood cancers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}